FavStocks » Biotech http://www.favstocks.com Stock Market News, Opinion, and More! Mon, 13 Feb 2012 08:24:09 +0000 en hourly 1 http://wordpress.org/?v=3.1 This Week’s Watchlist 2/13/12 http://www.favstocks.com/this-weeks-watchlist-21312/13872930/?utm_source=rss&utm_medium=rss&utm_campaign=this-weeks-watchlist-21312 http://www.favstocks.com/this-weeks-watchlist-21312/13872930/#comments Mon, 13 Feb 2012 08:16:04 +0000 Mike Havrilla http://www.favstocks.com/this-weeks-watchlist-21312/13872930/ http://www.favstocks.com/this-weeks-watchlist-21312/13872930/feed/ 0 This Week’s Catalyst Updates 2/12/12 http://www.favstocks.com/this-weeks-catalyst-updates-21212/13872931/?utm_source=rss&utm_medium=rss&utm_campaign=this-weeks-catalyst-updates-21212 http://www.favstocks.com/this-weeks-catalyst-updates-21212/13872931/#comments Mon, 13 Feb 2012 08:16:04 +0000 Mike Havrilla http://www.favstocks.com/this-weeks-catalyst-updates-21212/13872931/ http://www.favstocks.com/this-weeks-catalyst-updates-21212/13872931/feed/ 0 New Medical Device Trade for Mike http://www.favstocks.com/new-medical-device-trade-for-mike/11872628/?utm_source=rss&utm_medium=rss&utm_campaign=new-medical-device-trade-for-mike http://www.favstocks.com/new-medical-device-trade-for-mike/11872628/#comments Sat, 11 Feb 2012 08:16:05 +0000 Mike Havrilla http://www.favstocks.com/new-medical-device-trade-for-mike/11872628/ http://www.favstocks.com/new-medical-device-trade-for-mike/11872628/feed/ 0 $ECTE Symphony Glucose Monitoring System is Key Valuation Catalyst http://www.favstocks.com/ecte-symphony-glucose-monitoring-system-is-key-valuation-catalyst/09872202/?utm_source=rss&utm_medium=rss&utm_campaign=ecte-symphony-glucose-monitoring-system-is-key-valuation-catalyst http://www.favstocks.com/ecte-symphony-glucose-monitoring-system-is-key-valuation-catalyst/09872202/#comments Thu, 09 Feb 2012 08:16:03 +0000 Mike Havrilla http://www.favstocks.com/ecte-symphony-glucose-monitoring-system-is-key-valuation-catalyst/09872202/ Written by Mike Havrilla–Echo Therapeutics (NASDAQ:ECTE) is a medical device company focused on the development of new products based upon its advanced skin permeation technology platform.

FavStocks.com - $ECTE Symphony Glucose Monitoring System is Key Valuation Catalyst
Contributed by Mike Havrilla
Please visit FavStocks.com for more info on your Favorite Stocks. Also stop by the free Stock Forum and discuss todays hot stocks. )]]> http://www.favstocks.com/ecte-symphony-glucose-monitoring-system-is-key-valuation-catalyst/09872202/feed/ 0 New Phase 3 Catalyst Trade for Mike with Strong Balance Sheet http://www.favstocks.com/new-phase-3-catalyst-trade-for-mike-with-strong-balance-sheet/09872203/?utm_source=rss&utm_medium=rss&utm_campaign=new-phase-3-catalyst-trade-for-mike-with-strong-balance-sheet http://www.favstocks.com/new-phase-3-catalyst-trade-for-mike-with-strong-balance-sheet/09872203/#comments Thu, 09 Feb 2012 08:16:03 +0000 Mike Havrilla http://www.favstocks.com/new-phase-3-catalyst-trade-for-mike-with-strong-balance-sheet/09872203/ http://www.favstocks.com/new-phase-3-catalyst-trade-for-mike-with-strong-balance-sheet/09872203/feed/ 0 BioRunUp Webinar Notice http://www.favstocks.com/biorunup-webinar-notice/08871976/?utm_source=rss&utm_medium=rss&utm_campaign=biorunup-webinar-notice http://www.favstocks.com/biorunup-webinar-notice/08871976/#comments Wed, 08 Feb 2012 08:16:07 +0000 Mike Havrilla http://www.favstocks.com/biorunup-webinar-notice/08871976/ http://www.favstocks.com/biorunup-webinar-notice/08871976/feed/ 0 $EXAS Key Data for Colon Cancer Screening Test Expected Around 3Q12 http://www.favstocks.com/exas-key-data-for-colon-cancer-screening-test-expected-around-3q12/07871738/?utm_source=rss&utm_medium=rss&utm_campaign=exas-key-data-for-colon-cancer-screening-test-expected-around-3q12 http://www.favstocks.com/exas-key-data-for-colon-cancer-screening-test-expected-around-3q12/07871738/#comments Tue, 07 Feb 2012 08:16:02 +0000 Mike Havrilla http://www.favstocks.com/exas-key-data-for-colon-cancer-screening-test-expected-around-3q12/07871738/ Written by Mike Havrilla–EXACT Sciences (NASDAQ:EXAS) is a molecular diagnostics company focused on the late-stage development of a new non-invasive, genetic (DNA) based screening test (Cologuard) designed to improve the rate of early detection of colorectal cancer (CRC).

FavStocks.com - $EXAS Key Data for Colon Cancer Screening Test Expected Around 3Q12
Contributed by Mike Havrilla
Please visit FavStocks.com for more info on your Favorite Stocks. Also stop by the free Stock Forum and discuss todays hot stocks. )]]> http://www.favstocks.com/exas-key-data-for-colon-cancer-screening-test-expected-around-3q12/07871738/feed/ 0 2/6/12 Watchlist and Clinical Database Summary http://www.favstocks.com/2612-watchlist-and-clinical-database-summary/06871599/?utm_source=rss&utm_medium=rss&utm_campaign=2612-watchlist-and-clinical-database-summary http://www.favstocks.com/2612-watchlist-and-clinical-database-summary/06871599/#comments Mon, 06 Feb 2012 08:16:03 +0000 Mike Havrilla http://www.favstocks.com/2612-watchlist-and-clinical-database-summary/06871599/ http://www.favstocks.com/2612-watchlist-and-clinical-database-summary/06871599/feed/ 0 Trading Options around $CORT 2/17/12 http://www.favstocks.com/trading-options-around-cort-21712/04871297/?utm_source=rss&utm_medium=rss&utm_campaign=trading-options-around-cort-21712 http://www.favstocks.com/trading-options-around-cort-21712/04871297/#comments Sat, 04 Feb 2012 08:16:03 +0000 Mike Havrilla http://www.favstocks.com/trading-options-around-cort-21712/04871297/ http://www.favstocks.com/trading-options-around-cort-21712/04871297/feed/ 0 $ANAC Expects to Report Initial Phase 3 Data in Late 2012 http://www.favstocks.com/anac-expects-to-report-initial-phase-3-data-in-late-2012/02870856/?utm_source=rss&utm_medium=rss&utm_campaign=anac-expects-to-report-initial-phase-3-data-in-late-2012 http://www.favstocks.com/anac-expects-to-report-initial-phase-3-data-in-late-2012/02870856/#comments Thu, 02 Feb 2012 08:16:08 +0000 Mike Havrilla http://www.favstocks.com/anac-expects-to-report-initial-phase-3-data-in-late-2012/02870856/ Written by Mike Havrilla–Anacor Pharma (NASDAQ:ANAC) is focused on the mid to late stage clinical development of anti-fungal, antibiotic and anti-inflammatory therapeutics. Below is a summary of the Company’s pipeline.

FavStocks.com - $ANAC Expects to Report Initial Phase 3 Data in Late 2012
Contributed by Mike Havrilla
Please visit FavStocks.com for more info on your Favorite Stocks. Also stop by the free Stock Forum and discuss todays hot stocks. )]]> http://www.favstocks.com/anac-expects-to-report-initial-phase-3-data-in-late-2012/02870856/feed/ 0